Covered recipient · General Payments record
SCOT A NIGLIO
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$304.06
3 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $304.06 | 3 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | $154.89 | 2 |
| PFIZER INC. | $149.17 | 1 |
Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
SCOT A NIGLIO
NPI 1760828016 · CMS profile ID 8799026
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
NEW YORK, NY
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1760828016?year=2025&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- SCOT A NIGLIO, NPI 1760828016, CMS profile ID 8799026. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1760828016?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). SCOT A NIGLIO, NPI 1760828016, CMS profile ID 8799026. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1760828016?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- SCOT A NIGLIO, NPI 1760828016, CMS profile ID 8799026, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1760828016?year=2025&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
3 matching records · $304.06 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–3 of 3.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $27.43 | 04/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206362769 | CMS |
| AstraZeneca Pharmaceuticals LP | $127.46 | 03/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1207050433 | CMS |
| PFIZER INC. | $149.17 | 02/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1231362701 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2023, 2024, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $228,125.62 | 4 |
| PY2024 | Principal investigator | $1,291,441.34 | 47 |
| PY2023 | Principal investigator | $1,077,803.48 | 36 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
47 records in PY2024
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $42,312.81 | 12/31/2024 | Non-covered Recipient Entity Laura and Isaac Perlmutter Cancer Center | A Phase 1b,2 Study of Immune and Targeted Combination Therapies in Participants with RCC KEYMAKER-U03# Substudy 03A in First Line Metastatic Participants | No dispute reported | 06/30/2026 | 1136408562 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $42,312.81 | 12/31/2024 | Non-covered Recipient Entity Laura and Isaac Perlmutter Cancer Center | A Phase 1b,2 Study of Immune and Targeted Combination Therapies in Participants with RCC KEYMAKER-U03# substudy 03B in Second-Line Metastatic Participants | No dispute reported | 06/30/2026 | 1136409930 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $17,300.07 | 12/31/2024 | Non-covered Recipient Entity Perlmutter NYU Cancer Center | A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 and Pembrolizumab in Combination with Other Investigational Agents in Subjects with High-risk Non-muscle-Invasive Bladder Cancer NMIBC Unresponsive to Bacillus Calmette-Guerin BCG Therapy | No dispute reported | 06/30/2026 | 1136410153 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $86,295.00 | 12/31/2024 | Non-covered Recipient Entity New York University Perlmutter Cancer Center | A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy versus Perioperative Placebo Neoadjuvant Chemotherapy in Cisplatin-Eligible Participants with Muscle-invasive Bladder Cancer KEYNOTE-866 | No dispute reported | 06/30/2026 | 1136414645 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $5,383.10 | 12/31/2024 | Non-covered Recipient Entity New York University Perlmutter Cancer Center | A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy versus Perioperative Placebo Neoadjuvant Chemotherapy in Cisplatin-Eligible Participants with Muscle-invasive Bladder Cancer KEYNOTE-866 | No dispute reported | 06/30/2026 | 1136414649 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $49,815.36 | 12/31/2024 | Non-covered Recipient Entity Winthrop University Hospital | A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination With Chemoradiotherapy CRT versus CRT Alone in Participants with Muscle-invasive Bladder Cancer MIBC KEYNOTE-992 | No dispute reported | 06/30/2026 | 1136415561 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $32,800.41 | 12/31/2024 | Non-covered Recipient Entity Winthrop University Hospital | A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination With Chemoradiotherapy CRT versus CRT Alone in Participants with Muscle-invasive Bladder Cancer MIBC KEYNOTE-992 | No dispute reported | 06/30/2026 | 1136416836 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $67,122.05 | 12/31/2024 | Non-covered Recipient Entity New York University Perlmutter Cancer Center | A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination With Chemoradiotherapy CRT versus CRT Alone in Participants with Muscle-invasive Bladder Cancer MIBC KEYNOTE-992 | No dispute reported | 06/30/2026 | 1136417018 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $97,224.54 | 12/31/2024 | Non-covered Recipient Entity New York University Perlmutter Cancer Center | A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination With Chemoradiotherapy CRT versus CRT Alone in Participants with Muscle-invasive Bladder Cancer MIBC KEYNOTE-992 | No dispute reported | 06/30/2026 | 1136417022 |
| Principal investigator 1 | Eli Lilly and Company | $57,198.15 | 12/23/2024 | Non-covered Recipient Entity NEW YORK UNIVERSITY | A PHASE 1 TRIAL INVESTIGATING LY4101174, AN ANTIBODY-DRUG CONJUGATE TARGETING NECTIN-4, IN PARTICIPANTS WITH RECURRENT, ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1137363869 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $97,706.30 | 12/04/2024 | Non-covered Recipient Entity New York University Perlmutter Cancer Center | A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination With Chemoradiotherapy CRT versus CRT Alone in Participants with Muscle-invasive Bladder Cancer MIBC KEYNOTE-992 | No dispute reported | 06/30/2026 | 1136416716 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $17,910.70 | 12/04/2024 | Non-covered Recipient Entity Winthrop University Hospital | A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination With Chemoradiotherapy CRT versus CRT Alone in Participants with Muscle-invasive Bladder Cancer MIBC KEYNOTE-992 | No dispute reported | 06/30/2026 | 1136416757 |
| Principal investigator 1 | ABBVIE INC. | $1,620.00 | 10/23/2024 | Non-covered Recipient Entity NEW YORK UNIVERSITY | A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1100749768 |
| Principal investigator 1 | ABBVIE INC. | $2,450.25 | 10/23/2024 | Non-covered Recipient Entity NEW YORK UNIVERSITY | A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1100749770 |
| Principal investigator 1 | ABBVIE INC. | $3,500.00 | 10/23/2024 | Non-covered Recipient Entity NEW YORK UNIVERSITY | A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1100749772 |
| Principal investigator 1 | ABBVIE INC. | $4,900.50 | 10/23/2024 | Non-covered Recipient Entity NEW YORK UNIVERSITY | A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1100749826 |
| Principal investigator 1 | ABBVIE INC. | $4,083.75 | 10/23/2024 | Non-covered Recipient Entity NEW YORK UNIVERSITY | A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1100749828 |
| Principal investigator 1 | ABBVIE INC. | $3,250.00 | 10/23/2024 | Non-covered Recipient Entity NEW YORK UNIVERSITY | A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1100749830 |
| Principal investigator 1 | ABBVIE INC. | $1,620.00 | 10/23/2024 | Non-covered Recipient Entity NEW YORK UNIVERSITY | A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1100749832 |
| Principal investigator 1 | ABBVIE INC. | $2,862.00 | 10/23/2024 | Non-covered Recipient Entity NEW YORK UNIVERSITY | A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1100749834 |
| Principal investigator 1 | ABBVIE INC. | $5,000.00 | 10/23/2024 | Non-covered Recipient Entity NEW YORK UNIVERSITY | A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1100749864 |
| Principal investigator 1 | ABBVIE INC. | $300.00 | 10/23/2024 | Non-covered Recipient Entity NEW YORK UNIVERSITY | A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1100749866 |
| Principal investigator 1 | ABBVIE INC. | $2,457.00 | 10/23/2024 | Non-covered Recipient Entity NEW YORK UNIVERSITY | A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1100749868 |
| Principal investigator 1 | ABBVIE INC. | $765.45 | 10/23/2024 | Non-covered Recipient Entity NEW YORK UNIVERSITY | A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1100749870 |
| Principal investigator 1 | ABBVIE INC. | $3,024.00 | 10/23/2024 | Non-covered Recipient Entity NEW YORK UNIVERSITY | A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1100749872 |
| Principal investigator 1 | ABBVIE INC. | $3,267.00 | 10/23/2024 | Non-covered Recipient Entity NEW YORK UNIVERSITY | A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1100749874 |
| Principal investigator 1 | ABBVIE INC. | $24,502.50 | 10/23/2024 | Non-covered Recipient Entity NEW YORK UNIVERSITY | A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1100749982 |
| Principal investigator 1 | PFIZER INC. | $1,900.00 | 10/02/2024 | Non-covered Recipient Entity NEW YORK UNIVERSITY CANCER INSTITUTE | A DOSEESCALATION AND DOSEEXPANSION STUDY OF ENFORTUMAB VEDOTIN ASG22CE IN COMBINATION WITH PEMBROLIZUMAB ANDOR CHEMOTHERAPY FOR TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER | No dispute reported | 06/30/2026 | 1130934031 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $32,040.76 | 09/30/2024 | Non-covered Recipient Entity Laura and Isaac Perlmutter Cancer Center | A Phase 1b,2 Study of Immune and Targeted Combination Therapies in Participants with RCC KEYMAKER-U03# Substudy 03A in First Line Metastatic Participants | No dispute reported | 06/30/2026 | 1136408638 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $157.60 | 08/28/2024 | Non-covered Recipient Entity Perlmutter NYU Cancer Center | A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 and Pembrolizumab in Combination with Other Investigational Agents in Subjects with High-risk Non-muscle-Invasive Bladder Cancer NMIBC Unresponsive to Bacillus Calmette-Guerin BCG Therapy | No dispute reported | 06/30/2026 | 1136410157 |
| Principal investigator 1 | ABBVIE INC. | $8,274.15 | 08/27/2024 | Non-covered Recipient Entity NEW YORK UNIVERSITY | Study to Determine the Safety Tolerability Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1100737740 |
| Principal investigator 1 | Gilead Sciences, Inc. | $3,728.00 | 08/14/2024 | Non-covered Recipient Entity NEW YORK UNIVERSITY SCHOOL OF MEDICINE | Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy | No dispute reported | 06/30/2026 | 1118375091 |
| Principal investigator 1 | PFIZER INC. | $1,090.00 | 08/07/2024 | Non-covered Recipient Entity NEW YORK UNIVERSITY CANCER INSTITUTE | A DOSEESCALATION AND DOSEEXPANSION STUDY OF ENFORTUMAB VEDOTIN ASG22CE IN COMBINATION WITH PEMBROLIZUMAB ANDOR CHEMOTHERAPY FOR TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER | No dispute reported | 06/30/2026 | 1130934335 |
| Principal investigator 1 | PFIZER INC. | $26,015.00 | 07/03/2024 | Non-covered Recipient Entity NYU Langone Perlmutter Cancer Center | AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB VERSUS CHEMOTHERAPY WITH OPTIONAL MAINTENANCE THERAPY IN SUBJECTS WITH HER2 EXPRESSING PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER | No dispute reported | 06/30/2026 | 1130959348 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $142,000.00 | 06/13/2024 | Non-covered Recipient Entity NYU Perlmutter Cancer Center | A Phase 2a Study with Safety Run-in to Evaluate the Safety, Tolerability, and Preliminary Efficacy of FF-10832 Monotherapy or in Combination with Pembrolizumab in Patients with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1136397383 |
| Principal investigator 1 | PFIZER INC. | $820.00 | 06/05/2024 | Non-covered Recipient Entity NEW YORK UNIVERSITY CANCER INSTITUTE | A DOSEESCALATION AND DOSEEXPANSION STUDY OF ENFORTUMAB VEDOTIN ASG22CE IN COMBINATION WITH PEMBROLIZUMAB ANDOR CHEMOTHERAPY FOR TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER | No dispute reported | 06/30/2026 | 1130934246 |
| Principal investigator 1 | PFIZER INC. | $8,910.00 | 05/27/2024 | Non-covered Recipient Entity NYU Langone Perlmutter Cancer Center | A PHASE 2 MULTI COHORT OPEN LABEL MULTICENTER CLINICAL STUDY EVALUATING THE EFFICACY AND SAFETY OF DISITAMAB VEDOTIN RC48 ADC IN SUBJECTS WITH HER2 EXPRESSING LOCALLY ADVANCED UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA | No dispute reported | 06/30/2026 | 1130958667 |
| Principal investigator 1 | PFIZER INC. | $39,660.45 | 05/27/2024 | Non-covered Recipient Entity NYU Langone Perlmutter Cancer Center | A PHASE 2 MULTI COHORT OPEN LABEL MULTICENTER CLINICAL STUDY EVALUATING THE EFFICACY AND SAFETY OF DISITAMAB VEDOTIN RC48 ADC IN SUBJECTS WITH HER2 EXPRESSING LOCALLY ADVANCED UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA | No dispute reported | 06/30/2026 | 1130958673 |
| Principal investigator 1 | PFIZER INC. | $9,100.00 | 05/27/2024 | Non-covered Recipient Entity NYU Langone Perlmutter Cancer Center | A PHASE 2 MULTI COHORT OPEN LABEL MULTICENTER CLINICAL STUDY EVALUATING THE EFFICACY AND SAFETY OF DISITAMAB VEDOTIN RC48 ADC IN SUBJECTS WITH HER2 EXPRESSING LOCALLY ADVANCED UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA | No dispute reported | 06/30/2026 | 1130959342 |
| Principal investigator 1 | Gilead Sciences, Inc. | $3,728.00 | 04/19/2024 | Non-covered Recipient Entity NEW YORK UNIVERSITY SCHOOL OF MEDICINE | Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy | No dispute reported | 06/30/2026 | 1118375089 |
| Principal investigator 1 | Eli Lilly and Company | $108,604.99 | 04/17/2024 | Non-covered Recipient Entity NEW YORK UNIVERSITY | AN OPEN-LABEL, MULTICENTER STUDY OF LOXO-435 (LY3866288) IN ADVANCED SOLID TUMOR MALIGNANCIES WITH FGFR3 ALTERATIONS | No dispute reported | 06/30/2026 | 1137362837 |
| Principal investigator 1 | PFIZER INC. | $2,450.00 | 04/10/2024 | Non-covered Recipient Entity NEW YORK UNIVERSITY CANCER INSTITUTE | A DOSEESCALATION AND DOSEEXPANSION STUDY OF ENFORTUMAB VEDOTIN ASG22CE IN COMBINATION WITH PEMBROLIZUMAB ANDOR CHEMOTHERAPY FOR TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER | No dispute reported | 06/30/2026 | 1130933959 |
| Principal investigator 1 | Eli Lilly and Company | $4,924.14 | 03/18/2024 | Non-covered Recipient Entity NEW YORK UNIVERSITY | A PHASE 1 TRIAL INVESTIGATING LY4101174, AN ANTIBODY-DRUG CONJUGATE TARGETING NECTIN-4, IN PARTICIPANTS WITH RECURRENT, ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1137362833 |
| Principal investigator 1 | PFIZER INC. | $2,377.50 | 03/13/2024 | Non-covered Recipient Entity NEW YORK UNIVERSITY CANCER INSTITUTE | A DOSEESCALATION AND DOSEEXPANSION STUDY OF ENFORTUMAB VEDOTIN ASG22CE IN COMBINATION WITH PEMBROLIZUMAB ANDOR CHEMOTHERAPY FOR TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER | No dispute reported | 06/30/2026 | 1130934331 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $71,000.00 | 02/02/2024 | Non-covered Recipient Entity NYU Langone Hospital - Long Island | A Phase 2a Study with Safety Run-in to Evaluate the Safety, Tolerability, and Preliminary Efficacy of FF-10832 Monotherapy or in Combination with Pembrolizumab in Patients with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1136397378 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $142,000.00 | 01/31/2024 | Non-covered Recipient Entity Laura and Isaac Perlmutter Cancer Center at NYU Langone | A Phase 2a Study with Safety Run-in to Evaluate the Safety, Tolerability, and Preliminary Efficacy of FF-10832 Monotherapy or in Combination with Pembrolizumab in Patients with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1136397593 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $5,677.00 | 01/29/2024 | Non-covered Recipient Entity Laura and Isaac Perlmutter Cancer Center | A Phase 1b,2 Study of Immune and Targeted Combination Therapies in Participants with RCC KEYMAKER-U03# Substudy 03A in First Line Metastatic Participants | No dispute reported | 06/30/2026 | 1136408558 |